Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) EV/FCF
As of 5 November 2026, Insmed, Inc. (INSM) trades at a EV/FCF of −37.2×. Over the past ten years it has ranged from −48.4× (December 2025) to −2.6× (December 2018); the current reading is higher than 2% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −35.1× | — |
| FY2024 | −15.9× | — |
| FY2023 | −8.4× | — |
| FY2022 | −5.8× | — |
| FY2021 | −7.9× | — |
| FY2020 | −13.7× | — |
| FY2019 | −6.5× | — |
| FY2018 | −3.1× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −39.2× | — |
| Jun 2026 | −28.2× | — |
| Mar 2026 | −37.8× | — |
| Dec 2025 | −35.1× | — |
| 27 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BBIO BridgeBio Pharma, Inc. compare | −39.7× |
| INSM Insmed, Inc. | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| EXEL Exelixis, Inc. compare | 14.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 22.9× |
| INCY Incyte Corporation compare | 29.7× |
| ASND Ascendis Pharma A/S compare | 41.1× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement